In-vitro study of molecular-genetic cuase of cell resistance against selected drugs
Project goals
The aim of this study is the search for and validation of more markers of drug resistance (among the known as MDR1, MRP1 or BCRP) and possible genetic predisposing factors. By comparing the gene expression profile of both the parental and resistant cell-line, the specific role of ABC transporters in emerging drug resistance in context of other genes expression will be determined. Cell-lines genetically modified to over-express selected ABC transporter will be used in functional study and the specific substrate transport will be determined. Expected result of this study is finding and verification of genes concerning multidrug resistance which should be used as a markers for drug resistance early diagnosis.
Keywords
moleculargeneticsresistancedrugcell-lineABC-transportertransport
Public support
Provider
Ministry of Health
Programme
Population Health (National programme of research)
Call for proposals
Zdraví obyvatel 2 (SMZ020051A)
Main participants
—
Contest type
VS - Public tender
Contract ID
1A8696-4/2005
Alternative language
Project name in Czech
In-vitro studie molekulárně-genetických příčin buněčné rezistence vůči vybraným léčivům
Annotation in Czech
Úkolem této studie je vyhledání a ověření dalších markerů vzniku lékové rezistence (kromě již známých, jako MDR1 nebo BCRP) a vybraných případných genetických predisponujících faktorů. Získáním rezistentní buněčné linie a srovnáním exprese s mateřskou linií budou získána data, jejichž analýzou bude možné zjistit úlohu ABC transportérů při vzniku rezistence v souvislosti se změnou exprese dalších genů. Připravené nepříbuzné buněčné linie transfekované a zvýšeně exprimující daný ABC transportér budou použity při funkční studii a bude ověřena schopnost daného proteinu transportovat příslušné léčivo. Očekávaným výsledkem studie je vyhledání a funkční ověření genů podílejících se výraznou měrou na vzniku rezistence a použitelných dále jako markerů pro včasnou diagnostiku vznikající lékové rezistence.
Scientific branches
R&D category
NV - Nonindustrial research (Applied research excluded Industrial research)
CEP classification - main branch
EB - Genetics and molecular biology
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
FR - Pharmacology and apothecary chemistry
10603 - Genetics and heredity (medical genetics to be 3)
10604 - Reproductive biology (medical aspects to be 3)
10605 - Developmental biology
10608 - Biochemistry and molecular biology
10609 - Biochemical research methods
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30101 - Human genetics
30104 - Pharmacology and pharmacy
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
The problem of resistance to xenobiotics is significant for implications to therapy. It was tested cell lines resistant to the drug and control. The authors developed and validated in the laboratory manual monitoring the transport of controlled drugs.
Solution timeline
Realization period - beginning
Aug 1, 2005
Realization period - end
Dec 31, 2008
Project status
U - Finished project
Latest support payment
Mar 5, 2008
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP09-MZ0-1A-U/04:1
Data delivery date
Apr 6, 2010
Finance
Total approved costs
7,196 thou. CZK
Public financial support
6,751 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
445 thou. CZK
Recognised costs
7 196 CZK thou.
Public support
6 751 CZK thou.
0%
Provider
Ministry of Health
CEP
EB - Genetics and molecular biology
Solution period
01. 08. 2005 - 31. 12. 2008